Abstract: A composition includes a hybrid ligand. The hybrid ligand includes an amine group, an amide group or a sulfonamide group, and hydroxyl groups. A first method includes providing a solution containing a first polar analyte and a second polar analyte, applying the solution to a stationary phase including an immobilized hybrid ligand, applying an elution solvent to the stationary phase such that the first polar analyte and the second polar analyte pass through the stationary phase with different elution times, and collecting the first polar analyte at a first elution time and collecting the second polar analyte at a second elution time after the first elution time. A device of a packed column, a cartridge, a tube, a well plate, a membrane, or a planar thin-layer chromatography plate includes a solid support and a hybrid ligand coupled to the solid support. A second method forms an immobilized hybrid ligand.

Abstract: A composition includes a hybrid ligand. The hybrid ligand includes an amine group, an amide group or a sulfonamide group, and hydroxyl groups. A first method includes providing a solution containing a first polar analyte and a second polar analyte, applying the solution to a stationary phase including an immobilized hybrid ligand, applying an elution solvent to the stationary phase such that the first polar analyte and the second polar analyte pass through the stationary phase with different elution times, and collecting the first polar analyte at a first elution time and collecting the second polar analyte at a second elution time after the first elution time. A device of a packed column, a cartridge, a tube, a well plate, a membrane, or a planar thin-layer chromatography plate includes a solid support and a hybrid ligand coupled to the solid support. A second method forms an immobilized hybrid ligand.

Abstract: Nucleic acids are prepared by dissolving compounds containing them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatment of autoimmune disease.

Abstract: The present invention relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is subjected to a liquid-solid phase separation to cause the active agent to form small spherical that are substantially amorphous or non-crystalline and are injectable through fine gauge needles at high concentrations. The invention has special application for higher molecular weight proteins.

Abstract: Nucleic acids are prepared by dissolving compounds containing them in a suitable solvent or solvent system and forming microspheres from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nucleic acids is useful, such as in treatment of autoimmune disease.

Abstract: Compositions of spherical insulin particles having improved pulmonary application potentials and methods of forming and using these compositions are disclosed in the present application. In one clinical trial with 30 healthy male human subjects, no coughing was observed upon a single pulmonary administration of the spherical insulin particles at an insulin dose of 6.5 mg, nor during the 10-hour post dosing period.

Abstract: Inhalable spherical particles that contain an active agent having unexpectedly good bioavailability when compared to the expected bioavailability are disclosed. Inhalable spherical particles, particles of the agent that contain an amount of a cation such as zinc provide for further improvement in bioavailability.

Abstract: Surface-modified microparticles and methods of making and using such particles are disclosed. The surface modified microparticles include a preformed or core microparticle that contains at least one active agent. The outer surface of the preformed or core microparticle carries a net surface charge. A monolayer is associated with the outer surface of the preformed or core microparticle.

Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Abstract: The present invention relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is subjected to a liquid-solid phase separation to cause the active agent to form small spherical that are substantially amorphous or non-crystalline and are injectable through fine gauge needles at high concentrations. The invention has special application for higher molecular weight proteins.

Abstract: Nucleic acids are prepared by dissolving compounds containg them in a suitable solvent or solvent system and forming microshperes from the resulting solution. The microspheres are administered to an individual as protection from conditions where delivery of nuceic acids is useful, such as in treatment of autoimmune disease.

Abstract: The present invention is related to a method for preparing small spherical particles of an active agent by providing a solution in a single liquid phase. The single liquid phase comprises an active agent, a phase separation enhancing agent, and a first solvent. A phase change is induced at a controlled rate in the solution to cause a liquid-solid phase separation of the active agent and to form a solid phase and a liquid phase. The solid phase comprises solid small spherical particles of the active agent. The liquid phase comprises the phase separation enhancing agent and the solvent. The small spherical particles are substantially spherical and having a size from about 0.01 ?m to about 200 ?m.

Abstract: The present invention relates to methods of making and compositions of microencapsulated small particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is then subjected to a liquid-solid phase separation to cause the active agent to form solid spherical small particles in the solid phase while the PSEA and solvent comprising the liquid phase. The spherical small particles formed are then microencapsulated within a polymeric matrix using an emulsion/evaporation process.

Abstract: The present invention is related to a method for preparing small spherical particles of an active agent by providing a solution in a single liquid phase. The single liquid phase comprises an active agent, a phase separation enhancing agent, and a first solvent. A phase change is induced at a controlled rate in the solution to cause a liquid-solid phase separation of the active agent and to form a solid phase and a liquid phase. The solid phase comprises solid small spherical particles of the active agent. The liquid phase comprises the phase separation enhancing agent and the solvent. The small spherical particles are substantially spherical and having a size from about 0.01 ?m to about 200 ?m.

Abstract: The present invention relates to methods of making and compositions of microencapsulated small particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is then subjected to a liquid-solid phase separation to cause the active agent to form solid spherical small particles in the solid phase while the PSEA and solvent comprising the liquid phase. The spherical small particles formed are then microencapsulated within a polymeric matrix using an emulsion/evaporation process.

Abstract: The present invention is related to a method for preparing small spherical particles of an active agent by providing a solution in a single liquid phase. The single liquid phase comprises an active agent, a phase separation enhancing agent, and a first solvent. A phase change is induced at a controlled rate in the solution to cause a liquid-solid phase separation of the active agent and to form a solid phase and a liquid phase. The solid phase comprises solid small spherical particles of the active agent. The liquid phase comprises the phase separation enhancing agent and the solvent. The small spherical particles are substantially spherical and having a size from about 0.01 ?m to about 200 ?m.

Abstract: The present invention is related to a method for preparing small spherical particles of an active agent by providing a solution in a single liquid phase. The single liquid phase comprises an active agent, a phase separation enhancing agent, and a first solvent. A phase change is induced at a controlled rate in the solution to cause a liquid-solid phase separation of the active agent and to form a solid phase and a liquid phase. The solid phase comprises solid small spherical particles of the active agent. The liquid phase comprises the phase separation enhancing agent and the solvent. The small spherical particles are substantially spherical and having a size from about 0.01 ?m to about 200 ?m.